Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics Inc is recognized for its potential in the precision medicine sector, particularly with its lead candidate, stenoparib, which has demonstrated promising clinical benefits for patients with advanced recurrent ovarian cancer, showcasing a median overall survival exceeding 25 months in recent trials. The company’s utilization of proprietary Drug Response Predictor (DRP) technology further enhances its ability to target patients effectively, aiming to improve clinical outcomes significantly. With an attractive current valuation underscored by a positive net present value (NPV) analysis and substantial upside potential from the current share price, Allarity Therapeutics positions itself favorably within the competitive landscape of cancer therapeutics.

Bears say

The financial report indicates a net loss of $2.8 million, translating to an earnings per share (EPS) of $(0.19), which is slightly better than prior estimates but still indicative of ongoing financial challenges. Historical losses also reflect consistent negativity, with the previous net loss at $2.37 million and an EPS of $(0.15), raising concerns about sustainability and financial health in a clinical-stage company reliant on successful product development. Moreover, substantial risks related to the balance sheet, regulatory approvals, and competitive pressures further exacerbate uncertainties, contributing to a negative outlook for Allarity Therapeutics's stock performance.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.